← Back to all trials
Recruiting
NCT06856343
REBECCA Real-world Early BrEast CanCer mAnagement
Conditions: Breast Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 126
Sponsor: AstraZeneca
Location: Research Site Clermont-Ferrand Auvergne-Rh ne-Alpes
Summary
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Eligibility Criteria
Inclusion Criteria:
* Male or female aged ≥ 18 years
* Patient diagnosed with HER2-negative eBC
* Patient about to be initiated with adjuvant Olaparib at their physician's discretion
* Patient has been informed and does not object to participation in the study.
Exclusion Criteria:
* Patient not consenting to participate.
* Patients included in the Early Access Program
Source: ClinicalTrials.gov (NCT06856343). StuddyBuddy aggregates publicly available trial information.
